Changes in the colonic microbiota may play a role in the pathogenesis of ulcerative colitis (UC) and restoration of healthy gut microbiota may ameliorate disease.
Dr Nareej Narula and colleagues performed a systematic review and meta-analysis to assess fecal microbiota transplantation as a treatment for active UC.
The team conducted a literature search to identify high-quality studies of fecal microbiota transplantation as a treatment for patients with UC.
The researchers' primary outcome was combined clinical remission and endoscopic remission or response.
|Number needed to treat for remission with fecal microbiota transplantation was 5|
|Inflammatory Bowel Disease|
Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events.
Overall, 4 studies with 277 participants were eligible for inclusion.
The team found that among 4 randomized controlled trials, fecal microbiota transplantation was associated with higher combined clinical and endoscopic remission compared with placebo with a number needed to treat of 5.
There was no statistically significant increase in serious adverse events with fecal microbiota transplantation compared with controls.
Dr Narula's team comments, "Among randomized controlled trials, short-term use of fecal microbiota transplantation shows promise as a treatment to induce remission in active UC based on the efficacy and safety observed."
"However, there remain many unanswered questions that require further research before fecal microbiota transplantation can be considered for use in clinical practice."